Impact of Treatment Response on Quality of Life and Health-Related Utility Values in Hepatitis: A Targeted Literature Review
Author(s)
Barinder Singh, MPharm1, Shubhram Pandey, MSc1, Gagandeep Kaur, MPharm1, Marvin Rock, MPH, DrPH2, Chong H Kim, MPH, MS, PhD2;
1Pharmacoevidence Private Limited, Mohali, India, 2Gilead Sciences, Inc., Foster City, CA, USA
1Pharmacoevidence Private Limited, Mohali, India, 2Gilead Sciences, Inc., Foster City, CA, USA
Presentation Documents
OBJECTIVES: Hepatitis B, C, and delta virus (HBV, HCV, and HDV) infections are chronic liver diseases that significantly impact patient health, often leading to severe outcomes such as cirrhosis and liver cancer. This targeted literature review examined the association between treatment response and health-related quality of life (HRQoL) and utility values among patients with HBV, HCV, and HDV.
METHODS: The comprehensive search strategy used a combination of Emtree subject headings (from Embase), MeSH terms (from PubMed), and free-text keywords to capture relevant studies across all databases from inception to August 2024.
RESULTS: Of 812 identified citations, 4 systematic literature reviews and 67 studies investigated the relationship between treatment response and HRQoL or utility values. Of the 67 studies, 38 were journal articles, and 29 were conference abstracts. Most studies (n = 63) focused on HCV, 3 assessed HBV; the sample size ranged from 34 to 4,087 patients. Studies examining the association of treatment response with HRQoL revealed consistent improvements in HRQoL scores among responders. Among global studies (n = 11), patients who achieved sustained virologic response (SVR) generally showed better HRQoL scores compared with those who did not. This association was positive and statistically significant in most studies. Further, SVR positively impacted psychological distress and overall health status, with benefits maintained over time; patients who did not achieve SVR often experienced worsened HRQoL. Patients who achieved SVR had health-state utility values ranging 0.05-0.31 greater than those who did not respond to treatment.
CONCLUSIONS: These findings underscore the substantial impact of SVR on HRQoL, particularly in the domains of general health and vitality, and highlight the value of effective treatments in enhancing quality of life for patients with chronic viral hepatitis. Further research is encouraged to explore the quantitative synthesis of studies reporting on the relationship between SVR and HRQoL and utility values.
METHODS: The comprehensive search strategy used a combination of Emtree subject headings (from Embase), MeSH terms (from PubMed), and free-text keywords to capture relevant studies across all databases from inception to August 2024.
RESULTS: Of 812 identified citations, 4 systematic literature reviews and 67 studies investigated the relationship between treatment response and HRQoL or utility values. Of the 67 studies, 38 were journal articles, and 29 were conference abstracts. Most studies (n = 63) focused on HCV, 3 assessed HBV; the sample size ranged from 34 to 4,087 patients. Studies examining the association of treatment response with HRQoL revealed consistent improvements in HRQoL scores among responders. Among global studies (n = 11), patients who achieved sustained virologic response (SVR) generally showed better HRQoL scores compared with those who did not. This association was positive and statistically significant in most studies. Further, SVR positively impacted psychological distress and overall health status, with benefits maintained over time; patients who did not achieve SVR often experienced worsened HRQoL. Patients who achieved SVR had health-state utility values ranging 0.05-0.31 greater than those who did not respond to treatment.
CONCLUSIONS: These findings underscore the substantial impact of SVR on HRQoL, particularly in the domains of general health and vitality, and highlight the value of effective treatments in enhancing quality of life for patients with chronic viral hepatitis. Further research is encouraged to explore the quantitative synthesis of studies reporting on the relationship between SVR and HRQoL and utility values.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR161
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Infectious Disease (non-vaccine)